Boosting anticancer vaccines: Too much of a good thing?
Using both transplantable and oncogene-driven autochthonous tumor models challenged with dendritic cell-based vaccines, we have recently found that boosting provides a clear advantage in prophylactic settings, unless performed on an excessively tight schedule, which causes the loss of central memory T cells. In therapeutic settings, boosting turned out to be always detrimental.
Cellular Immunology Unit; San Raffaele Scientific Institute; Milan, Italy.
Alessia
A
Ricupito
Matteo
M
Grioni
Arianna
A
Calcinotto
Matteo
M
Bellone
B16; T cell; TRAMP; adjuvant; cancer; cytotoxic T lymphocytes; melanoma; memory; prostate cancer; vaccines